Please login to the form below

Not currently logged in
Email:
Password:

meningococcal B disease

This page shows the latest meningococcal B disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer wins EU approval for MenB vaccine Trumenba

Pfizer wins EU approval for MenB vaccine Trumenba

The EU approval comes two-and-a-half years after Trumenba was green-lighted by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B, which is ... It is important to have multiple tools at our disposal to

Latest news

  • Pfizer posts positive Trumenba vaccine data Pfizer posts positive Trumenba vaccine data

    Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... Trumenba was approved by the FDA in 2014 to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B.

  • Pfizer gets FDA nod for meningitis vaccine Trumenba Pfizer gets FDA nod for meningitis vaccine Trumenba

    Trumenba - formerly known as rLP2086 - has been approved by the FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10 to 25, a strain which ... Invasive meningococcal disease is a life-threatening

  • US panel backs pneumococcal vaccines for seniors US panel backs pneumococcal vaccines for seniors

    The ACIP recommendations now go to the Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) for review and approval. ... Separately, Pfizer also said that the FDA has accepted its marketing application for

  • Pfizer's meningitis vaccine 'a breakthrough' Pfizer's meningitis vaccine 'a breakthrough'

    Aside from the risk of death, meningococcal B disease can also lead to long-term disabilities such as brain damage and hearing loss. ... The breakthrough therapy designation highlights the urgent need for prevention of meningococcal B disease," he added.

  • Research into meningococcal B disease Research into meningococcal B disease

    Multicomponent meningococcal serogroup B vaccine or 4CMenB (Bexsero, Novartis) was approved in the EU for the immunisation against invasive meningococcal disease (IMD) caused by the bacterium Neisseria meningitidis serogroup B in ... Looking ahead.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics